Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My NCBI Filters

Results by year

Table representation of search results timeline featuring number of search results per year.

Year Number of Results
2004 1
2008 1
2010 2
2011 2
2012 4
2013 3
2014 4
2015 7
2016 7
2017 7
2018 6
2019 17
2020 12
2021 13
2022 15
2023 20
2024 11

Text availability

Article attribute

Article type

Publication date

Search Results

118 results

Results by year

Filters applied: . Clear all
Page 1
Exploratory biomarker analysis in the phase III L-MOCA study of olaparib maintenance therapy in patients with platinum-sensitive relapsed ovarian cancer.
Li H, Peng Z, Zhu J, Zhao W, Huang Y, An R, Zheng H, Qu P, Wang L, Zhou Q, Wang D, Lou G, Wang J, Wang K, Kong B, Xie X, Yin R, Low J, Rozita AM, Sen LC, Meng YC, Kiong KS, Liu J, Liang Z, Lv W, Zhu Y, Hu W, Sun W, Su J, Wang Q, Zang R, Ma D, Gao Q. Li H, et al. Among authors: zhu j. BMC Med. 2024 May 16;22(1):199. doi: 10.1186/s12916-024-03409-9. BMC Med. 2024. PMID: 38755585 Free PMC article. Clinical Trial.
Senaparib as first-line maintenance therapy in advanced ovarian cancer: a randomized phase 3 trial.
Wu X, Liu J, Wang J, Wang L, Lin Z, Wang X, Zhu J, Kong B, Fei J, Tang Y, Xia B, Liang Z, Wang K, Huang Y, Zheng H, Lin A, Jiang K, Wang W, Wang X, Lou G, Pan H, Yao S, Li G, Hao M, Cai Y, Chen X, Yang Z, Chen Y, Wen H, Qu P, Xu C, Hsieh CY; FLAMES Investigators. Wu X, et al. Among authors: zhu j. Nat Med. 2024 May 15. doi: 10.1038/s41591-024-03003-9. Online ahead of print. Nat Med. 2024. PMID: 38750351
Niraparib maintenance therapy using an individualised starting dose in patients with platinum-sensitive recurrent ovarian cancer (NORA): final overall survival analysis of a phase 3 randomised, placebo-controlled trial.
Wu X, Zhu J, Yin R, Yang J, Liu J, Wang J, Wu L, Liu Z, Gao Y, Wang D, Lou G, Yang H, Zhou Q, Kong B, Huang Y, Chen L, Li G, An R, Wang K, Zhang Y, Yan X, Lu X, Lu W, Hao M, Wang L, Cui H, Chen Q, Abulizi G, Huang X, Tian X, Wen H, Huang Z, Dong J, Zhang C, Hou J, Mirza MR. Wu X, et al. Among authors: zhu j. EClinicalMedicine. 2024 May 7;72:102629. doi: 10.1016/j.eclinm.2024.102629. eCollection 2024 Jun. EClinicalMedicine. 2024. PMID: 38745967 Free PMC article.
Shanghai Gynecologic Oncology Group's Consensus on the academic and industry's clinical trial types.
Shi T, Liu J, Zhu J, Wang X, Jiang W, Lu X, Feng W, Zhou S, Shen Y, Chen G, Wu Z, Zou D, Wu P, Yang H, Wu S, Zhu T, Wang H, Zhang Y, Qiu L, Guo X, Xiang L, Zhang W, Ren Y, Feng Y, Liu Y, Chen X, Zang R; Shanghai Gynecologic Oncology Group (SGOG). Shi T, et al. Among authors: zhu j. Chin Med J (Engl). 2024 Apr 24. doi: 10.1097/CM9.0000000000003146. Online ahead of print. Chin Med J (Engl). 2024. PMID: 38654409 No abstract available.
118 results